Prevalence of systemic sclerosis in Split–Dalmatia county in Southern Croatia

Radić, Mislav; Kaliterna, Dušanka Martinović; Fabijanić, Damir; Radić, Josipa

doi:10.1007/s10067-009-1341-6

Cited by 22 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study estimated incidence and prevalence in the UK to be higher than previously reported in Norway, Croatia, Greece, France, Taiwan, and Australia [6, 7, 10, 12, 13, 16], similar to the USA, Sweden, and Spain [11, 14, 15], and lower than in Italy and Canada [3, 4]. Our findings were consistent with other large population-based studies in Caucasians.…”

Section: Discussionsupporting

confidence: 90%

“…Studies published since this have continued to report high incidences in Southern Europe (Spain, Croatia and Italy) [3, 11, 12] but contradictory rates in Northern Europe with low annual incidence of 6–11 per million in Norway [13] and a higher rate 19/million person-years in Southern Sweden [14]. Incidence and prevalence in the USA, Canada, and Australia are reported at the higher end of this range [4, 15, 16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink

et al. 2018

View full text Add to dashboard Cite

To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of systemic sclerosis between 1994 and 2013 and examined its association with age, sex, and socioeconomic status. We calculated point prevalence on 1 July 2013 and examined its association with the same exposures. We identified 1327 cases with incident systemic sclerosis. Annual incidence was 19.4 per million person-years between 1994 and 2013. The incidence was 4.7 times higher in women than in men, was not influenced by socioeconomic status, and has remained stable over the 20 year study period. The peak age of onset was 55–69 years. Survival at 1, 5, and 10 years was 94.2, 80.0, and 65.7%, respectively. The prevalence was 307 (290–323) per million with the highest prevalence in the 70–84 years age group. We estimate there are currently 1180 new cases of systemic sclerosis each year in the UK, and 19,390 people living with systemic sclerosis. Due to the predicted growth and aging of the population, we predict a 24% increase in incident cases and 26% increase in prevalent cases in 20 years’ time. Our estimates of incidence and prevalence are higher than previously reported in the UK, but similar to recent USA and Swedish studies, and do not support a north-south gradient of the occurrence of systemic sclerosis in Europe.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The estimated point prevalence was 27.7 cases per 100 000 persons, and the estimated mean annual incidence was 2.3 cases per 100 000 persons per year . Radic et al conducted a retrospective analysis of medical records from Split University Hospital in Split‐Dalmatia County, Croatia, to estimate the prevalence of SSc during 2008 . The 1‐year prevalence was 15.6 cases per 100 000 persons in southern Croatia using the 1980 ACR criteria only .…”

Section: Resultsmentioning

confidence: 99%

“…Radic et al conducted a retrospective analysis of medical records from Split University Hospital in Split‐Dalmatia County, Croatia, to estimate the prevalence of SSc during 2008 . The 1‐year prevalence was 15.6 cases per 100 000 persons in southern Croatia using the 1980 ACR criteria only . Bajraktari et al conducted a retrospective analysis of medical records in the municipalities of Dukagjini Plain, Kosovo, to estimate the 2010 point prevalence and the mean annual incidence of SSc during a 6‐year period, from 2005 to 2010 .…”

Section: Resultsmentioning

confidence: 99%

“…The overall prevalence was 27.7 per 100 000 persons in northwestern Spain . In southern Croatia, an overall prevalence of 15.6 per 100 000 persons was reported using the 1980 ACR criteria; this prevalence might have been higher had the LeRoy and Medsger criteria been applied . In Kosovo, an overall prevalence of 14.6 per 100 000 persons was reported .…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Prevalence and incidence of systemic sclerosis: A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Objective Systemic sclerosis (SSc) is a rare debilitating autoimmune disease of the connective tissue. This study aimed to assess the recent prevalence and incidence of SSc across the world. Methods Using a systematic search strategy, PubMed/MEDLINE and EMBASE were searched to identify relevant studies published between 2006 and 2016. Two reviewers independently evaluated studies for inclusion based on inclusion/exclusion criteria and performed data extraction. The review was conducted and reported following the Preferred Reporting Items for Systematic Review and Meta‐analysis (PRISMA) statement. The pooled prevalence of SSc was calculated by meta‐analysis using a random‐effects model. Results There were 1364 references retrieved using the initial searching strategy, and 20 epidemiological publications were selected for data extraction. The identified studies reported prevalence ranging from 3.8 per 100 000 in Taiwan to 50 per 100 000 in the USA. The prevalence was 23 per 100 000 (95% CI: 16‐29 per 100 000; 18 studies) in a pooled sample of 11 574 individuals. Incidence rate of SSc ranges from 0.77 per 100 000 person‐years in the Netherlands to 5.6 per 100 000 person‐years in the USA. SSc predominates in females with higher prevalence and incidence rates. It is important to note that different methodologies were used to derive these numbers so comparisons were made with caution. Conclusion This review provides an assessment of the current estimates of disease prevalence and incidence of SSc. The epidemiological burdens of SSc vary among different regions of the world. The epidemiological data need to be interpreted with caution considering the methodological differences in deriving these estimates.

show abstract